U.S. markets open in 6 hours 58 minutes
  • S&P Futures

    3,428.50
    -23.25 (-0.67%)
     
  • Dow Futures

    27,995.00
    -194.00 (-0.69%)
     
  • Nasdaq Futures

    11,607.00
    -56.50 (-0.48%)
     
  • Russell 2000 Futures

    1,618.90
    -16.70 (-1.02%)
     
  • Crude Oil

    38.94
    -0.91 (-2.28%)
     
  • Gold

    1,897.40
    -7.80 (-0.41%)
     
  • Silver

    24.23
    -0.45 (-1.82%)
     
  • EUR/USD

    1.1839
    -0.0030 (-0.25%)
     
  • 10-Yr Bond

    0.8410
    0.0000 (0.00%)
     
  • Vix

    27.55
    -0.56 (-1.99%)
     
  • GBP/USD

    1.3024
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.8400
    +0.1500 (+0.14%)
     
  • BTC-USD

    13,105.10
    +9.65 (+0.07%)
     
  • CMC Crypto 200

    263.19
    +1.73 (+0.66%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman

Zacks Equity Research
·5 mins read

For Immediate Release

Chicago, IL – September 31, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Verizon Communications Inc. VZ, Novartis AG NVS, Abbott Laboratories ABT, AT&T Inc. T, Intuitive Surgical, Inc. ISRG and Northrop Grumman Corporation NOC.

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Verizon, Novartis and Abbott Labs

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications, Novartis and Abbott Laboratories. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Verizon shares have lagged the Zacks Wireless National industry in the year to date period (-3.9% vs. -1.3%), though it has handily outperformed rival AT&T on the back of stable financial profile and a disciplined network strategy, including accelerated 5G deployment despite economic uncertainties stemming from the COVID-19 crisis.

The company is changing its revenue mix toward newer growth services like cloud, security and professional services. Focus on online content delivery, mobile video and online advertising should stoke additional growth. Verizon expects to witness strong momentum heading into the second half of 2020, with continued 5G Ultra Wideband deployment in multiple cities across the country.

However, it is facing headwinds in the media business due to sluggish advertising trends. The company operates in a fiercely-competitive U.S. wireless market that strains margins. Also, Verizon is spending heavily on promotion and lucrative discounts to attract customers, which erodes profitability.

(You can read the full research report on Verizon here >>>)

Shares of Novartis have lost -0.6% over the past six months against the Zacks Large-Cap Pharmaceuticals industry’s rise of +7.4%. The Zacks analyst believes that Novartis has a strong oncology portfolio and continues to work on developing its immuno-oncology pipeline. Besides, Sandoz is working on further advancing its portfolio of biosimilars and generics.

However, the company tightened its outlook for 2020 due to the pandemic woes. Nevertheless, Cosentyx and Entresto gained a decent market share amid the current scenario. Piqray, Mayzent and Beovu should boost sales too further. The biosimilar portfolio also gains traction from key new approvals. However, pipeline setbacks and generic competition are concerning.

(You can read the full research report on Novartis here >>>)

Abbott shares have gained +17.4% over the past three months against the Zacks Medical Products industry’s rise of +5.5%. The Zacks analyst believes that the branded generics and international diabetes businesses should drive growth in the coming quarters. New product launches and acquisitions should boost sales further.

Abbott posted better-than-expected numbers for the second quarter. However, the figures declined year over year. Despite $615 million of COVID-19 diagnostic testing-related sales, this decline was primarily due to the pandemic-led fall in procedure volumes in many businesses.

However, the company’s Diabetes Care, Nutrition, and EPD arms collectively grew more than 9% in the first half of 2020 leveraging on the pandemic situation. Apart from the latest EUA for COVID-19 rapid antigen test, the company also obtained FDA for Libre 2 as an iCGM. It also received CE Mark for TriClip.

(You can read the full research report on Abbott here >>>)

Other noteworthy reports we are featuring today include Intuitive Surgical and Northrop Grumman.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.

This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.

See their latest picks free >>

 

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                                   

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Northrop Grumman Corporation (NOC) : Free Stock Analysis Report
 
ATT Inc. (T) : Free Stock Analysis Report
 
Verizon Communications Inc. (VZ) : Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
 
Abbott Laboratories (ABT) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research